Owners, management and financials
CVR: 35818790
Previous names: ARIAD PHARMACEUTICALS (DENMARK) ApS
DKK 6,696,586
Gross profit
Net result: DKK 361,151
Incyte Biosciences International Sàrl (100%)
CVR · view owners
Ebba Cecilia Bröms
Board: Lee Jason Heeson (chair) and 1 member
CVR · view management
Active
Founded 1 April 2014
CVR · view overview
2 employees
CVR · 2018
Director role ended: Erik Garardus Johannes Bokmans
CVR · 25/02/2026
View the full event history
Incyte Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Frederiksberg C, founded in 2014. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ARIAD PHARMACEUTICALS (DENMARK) ApS. The management consists of Ebba Cecilia Bröms. The board consists of Lee Jason Heeson (chair) and Ebba Cecilia Bröms. The company is owned by Incyte Biosciences International Sàrl. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 6,696,586 and a net result of DKK 361,151 compared with DKK 368,873 the year before. Equity in the 2025 report amounted to DKK 2,328,496.
Source: annual report 2025, Danish Business Authority
The financial health of Incyte Biosciences Denmark ApS appears stable, with consistent gross profit growth over the past five years, increasing from 5,287,823 DKK in 2021 to 6,696,586 DKK in 2025. Profitability has also remained relatively steady, with profits ranging from 268,531 DKK to 374,584 DKK during the same period. The company's equity has shown a positive trajectory, rising from 945,939 DKK in 2021 to 2,328,496 DKK in 2025, indicating a strengthening financial position. However, the absence of disclosed revenue raises concerns about overall sales performance and market position within the pharmaceutical wholesale industry.
AI-generated summary · Generated 14/08/2026
Selskabets formål er at udbrede medicinsk og farmaceutisk viden og aktivitet, handel med medicinalvareprodukter samt enhver virksomhed som er beslægtet hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 6.7 mio. | 361 t. | 4 mio. | 2.3 mio. | 4 | |
| 202401/01/2024 – 31/12/2024 | 7 mio. | 369 t. | 3.7 mio. | 2 mio. | 4 | |
| 202301/01/2023 – 31/12/2023 | 6.3 mio. | 375 t. | 4.6 mio. | 1.6 mio. | 4 | |
| 202201/01/2022 – 31/12/2022 | 5.6 mio. | 278 t. | 7 mio. | 1.2 mio. | 4 | |
| 202101/01/2021 – 31/12/2021 | 5.3 mio. | 269 t. | 3.4 mio. | 946 t. | 4 | |
| 202001/01/2020 – 31/12/2020 | 5.4 mio. | 150 t. | 3.4 mio. | 677 t. | 3 | |
| 201901/01/2019 – 31/12/2019 | 4.8 mio. | 286 t. | 2.4 mio. | 527 t. | 3 | |
| 201801/01/2018 – 31/12/2018 | 3 mio. | 87 t. | 1.3 mio. | 241 t. | 2 | |
| 201701/01/2017 – 31/12/2017 | 2 mio. | 47 t. | 1.8 mio. | 154 t. | 1 | |
| 201601/01/2016 – 31/12/2016 | 1.5 mio. | 25 t. | 995 t. | 107 t. | - | |
| 201501/01/2015 – 31/12/2015 | 1.5 mio. | 26 t. | 987 t. | 82 t. | - |
Compared to 405 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorThe CVR number of Incyte Biosciences Denmark ApS is 35818790.
Incyte Biosciences Denmark ApS is owned by Incyte Biosciences International Sàrl.
The management of Incyte Biosciences Denmark ApS consists of Ebba Cecilia Bröms.
The board of Incyte Biosciences Denmark ApS consists of Lee Jason Heeson and Ebba Cecilia Bröms, with Lee Jason Heeson as chair.
In 2025, Incyte Biosciences Denmark ApS reported a gross profit of DKK 6,696,586.
Incyte Biosciences Denmark ApS had 2 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Incyte Biosciences Denmark ApS has published its annual report for 2025. Gross profit came to DKK 6,696,586, and the net result was DKK 361,151.
Contact info changed: new phone: 20663890, new email: [email protected] (February 27, 2026).
As of February 25, 2026, Ebba Cecilia Bröms has joined the board of directors of Incyte Biosciences Denmark ApS.
As of February 25, 2026, Erik Garardus Johannes Bokmans has left the board of directors of Incyte Biosciences Denmark ApS.
As of February 25, 2026, Ebba Cecilia Bröms is registered as director of Incyte Biosciences Denmark ApS.
As of February 25, 2026, Erik Garardus Johannes Bokmans has stepped down as director of Incyte Biosciences Denmark ApS.
Incyte Biosciences Denmark ApS has published its annual report for 2024. Gross profit came to DKK 7,046,348, and the net result was DKK 368,873.
As of February 27, 2025, Erik Garardus Johannes Bokmans has joined the board of directors of Incyte Biosciences Denmark ApS.
As of February 27, 2025, Erik Thomas Fromm has left the board of directors of Incyte Biosciences Denmark ApS.
As of February 27, 2025, Erik Garardus Johannes Bokmans is registered as director of Incyte Biosciences Denmark ApS.
As of February 27, 2025, Erik Thomas Fromm has stepped down as director of Incyte Biosciences Denmark ApS.
As of October 1, 2024, Lee Jason Heeson has joined the board of directors of Incyte Biosciences Denmark ApS.
As of September 30, 2024, Jonathan Elliot Dickinson has left the board of directors of Incyte Biosciences Denmark ApS.
Incyte Biosciences Denmark ApS has published its annual report for 2023. Gross profit came to DKK 6,283,403, and the net result was DKK 374,584.
As of April 12, 2024, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of Incyte Biosciences Denmark ApS.
Incyte Biosciences Denmark ApS has published its annual report for 2022. Gross profit came to DKK 5,556,640, and the net result was DKK 277,949.
Incyte Biosciences Denmark ApS has published its annual report for 2021. Gross profit came to DKK 5,287,823, and the net result was DKK 268,531.
Incyte Biosciences Denmark ApS has published its annual report for 2020. Gross profit came to DKK 5,397,378, and the net result was DKK 150,425.
Incyte Biosciences Denmark ApS has published its annual report for 2019. Gross profit came to DKK 4,829,925, and the net result was DKK 285,661.
Incyte Biosciences Denmark ApS has published its annual report for 2018. Gross profit came to DKK 3,030,527, and the net result was DKK 87,321.
Incyte Biosciences Denmark ApS has published its annual report for 2017. Gross profit came to DKK 2,043,465, and the net result was DKK 46,870.
As of May 15, 2017, is registered as an owner of Incyte Biosciences Denmark ApS with an ownership share of 100%.
Incyte Biosciences Denmark ApS has published its annual report for 2016. Gross profit came to DKK 1,494,675, and the net result was DKK 25,251.
On July 18, 2016, the company changed its name from ARIAD PHARMACEUTICALS (DENMARK) ApS to Incyte Biosciences Denmark ApS.
Incyte Biosciences Denmark ApS has published its annual report for 2015. Gross profit came to DKK 1,532,406, and the net result was DKK 26,475.
Incyte Biosciences Denmark ApS has published its interim report for the period April 1, 2014 – December 31, 2014.
As of April 1, 2014, Erik Thomas Fromm has joined the board of directors of Incyte Biosciences Denmark ApS.
As of April 1, 2014, Jonathan Elliot Dickinson has joined the board of directors of Incyte Biosciences Denmark ApS.
As of April 1, 2014, Erik Thomas Fromm is registered as director of Incyte Biosciences Denmark ApS.
Incyte Biosciences Denmark ApS was founded on April 1, 2014.
Companies in the same industry and area
CVR 37626619
CVR 44476533
CVR 33860463
CVR 35234748
CVR 39762560
